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TCD N¼403 CONV
N¼311
p-value
CMV Serology
R+/D+ 109 (27%) 104 (33.4%) 0.1665
R+/D- 86 (21.3%) 54 (17.4%) 0.5219*
R-/D+ 46 (11.4%) 41 (13.2%)
R-/D- 162 (40.2%) 112 (36%)
HLA
MRD 182 (45.2%) 171 (55%) 0.0092
Mismatched
or Unrelated
221 (54.8%) 140 (45.0%)
Stem Cell Source
Bone Marrow 76 (18.9%) 52 (16.7%) 0.4602
PBSC 327 (81.1%) 259 (83.3%)
CMV Prophylaxis
Yes 64 (15.9%) 45 (14.5%) 0.6031
No 339 (84.1%) 266 (85.5%)
CMV
reactivation,
number of
patients (%)
135 (33.5%) 86 (27.7%) 0.0939
Clinically
signiﬁcant
reactivation,
number
of patients (%)
111 (27.5%) 64 (20.6%) 0.0319
Median days
to ﬁrst
antigenemia
(range)
31 (10 to 585) 41.5 (10
to 384)
<0.0001
Peak number of
CMV-positive
cells, median
(range)
5 (1 to 100) 3 (1 to 100) 0.0159
Median
duration,
days (range)
11 (1 to 258) 8 (1 to 107) 0.0042
CMV Disease,
number of
patients (%)
16 (4%) 7 (2.3%) 0.197
TCD indicates, T-cell depleted transplant; CONV, unmodiﬁed transplant;
CMV, cytomegalovirus; R+, recipient seropositive; R-, recipient seronega-
tive; D+, donor seropositive; D-, donor seronegative; HLA, human leukocyte
antigen; MRD, matched related donor; PBSC, peripheral blood stem cells;
* Comparing recipient seropositivity between TCD and unmodiﬁed graft
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but increased incidence of grade II aGVHD after dUCBT (28%)
compared to 17% after sUCBT (p¼0.05). CI of chronic GvHD at
2 years was 21% after dUCBTand 12% after sUCBT (p¼0.15). At
2 years, CI of non relapse mortality (NRM) was 28% after
dUCBT and 30% after sUCBT (p¼0.87). CI of 2y RI was 21%
after dUCBT whereas it was 38% after sUCBT (p¼0.03). In
a multivariate analysis adjusting for the differences between
the 2 groups, dUCBT was associated with lower RI compared
to sUCBT (HR¼0.74, p¼0.01). Therefore, there was an
improved 2-y LFS after dUCBT (51%) compared to sUCBT
(32%; p¼0.03). This was conﬁrmed in a multivariate analysis
(HR¼0.64, p¼0.04).
Concerning pts transplanted in CR2 (n¼148), there were
no differences of outcomes after dUCBT (n¼93) or sUCBT
(n¼55). At 2y, LFS was 40% after dUCBT and 48% after sUCBT
(p¼0.32). In a subgroup analysis of dUCBT (n¼118) and
sUCBT (n¼51) recipients using the same conditioning
regimen (CYþFLUþTBI2Gy), 2 y LFS were 54% and 33%
respectively (p¼0.05).
In this retrospective comparative based registry analysis,
in AL pts transplanted in CR1, neutrophil recovery, GVHD and
NRM were not statistically different after RIC-dUCBT or RIC-
sUCBT, however, dUCBT recipients had decreased RI and
improved LFS. For AL pts transplanted in CR2, there was no
beneﬁt of using dUCBT when compared to sUCBT.
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Cytomegalovirus (CMV) is a major cause of mortality and
morbidity in hematopoietic stem cell transplantation (HSCT).
Transfer of CMV-speciﬁc T-cells from the donor is important
for the control of CMV replication after HSCT. In this study,
we compared incidence and kinetics of CMV infection and
CMV disease between T-cell depleted (TCD) and unmodiﬁed
(CONV) HSCT.
Methods: The cohort consisted of 714 adult HSCT recipients
of bone marrow or peripheral blood stem cell allografts from
September 1999 to March 2010 at Memorial Sloan-Kettering
Cancer Center. Patients were followed until July 2012. TCD
recipients did not receive any additional prophylactic
medicinal immunosuppression for graft-vs-host disease
(GvHD). CMV infection was monitored by PP65 antigenemia
assay (CMV Ag) if recipient or donor were CMV seropositive
and the information was prospectively stored in a comput-
erized database. Prior to 2007, recipients of mismatched
or unrelated allografts were eligible for CMV prophylaxis
if recipient or donor were CMV seropositive. Anti-CMV
agents were given to patients who had >¼ 2 cells per slide
(cps) on 1 occasion or 1 cps on >¼ 2 consecutive occasions.
Relapse, second transplant, death, and study termination
(April, 2012) were considered as competing risk for CMV
reactivation.
Results: Four hundred and three (56.5%) patients received
TCD grafts and 311 (43.6%) received unmodiﬁed grafts
(CONV). Recipient CMV seropositivity was 48.3% in TCD and
50.8% in CONV (p¼0.5219). There are 221 (54.8%) TCD and140 (45.0%) CONV patients received allograft from mis-
matched or unrelated donors (p¼0.0092). Sixty-four (15.9%)
TCD and 45 (14.5%) CONV patients received CMV prophylaxis
(p¼0.6031). CMV infections occurred in 135 (33.5%) TCD and
86 (27.7%) CONV patients. Two hundred and ﬁve (92.8%) of
the 221 infections developed by day þ100 post-transplant.
CMV infections requiring antiviral treatment occurred in 111
(27.5%) TCD and 64 (20.6%) CONV patients (p¼0.0319). Days
from HSCT to ﬁrst CMV infection were median 31 in TCD and
41.5 in CONV (p<0.0001). Maximum cps were median 5
(range 1 to 100) cps in TCD and 3 (1 to 100) cps in CONV
(p¼0.0159). Duration of reactivation was median 11 days in
TCD and 8 days in CONV patients (p¼0.0042). CMV disease
was diagnosed in 4% in TCD patients and 2.3% in CONV
patients (p¼0.197).
Conclusion: 1) Rates of CMV infection were similar in TCD
and CONV allogeneic HSCT; 2) In contrast, the kinetics of
CMV replication were different between the 2 groups: In
TCD, CMV infection occurred earlier, with higher peak level,
and longer duration of viremia 3) Rates of CMV disease were
low and similar between TCD and CONV (4% and 2.3%
respectively) Our data suggests that preemptive treatment
based on antigenemia is similarly effective for prevention of
CMV disease in TCD and CONV allografts.
